Find Academic Supervisors

Michael J. CimaView profile

Professor

• Medical Devices
• Materials Science
• Drug Delivery Systems
• +7 more

Michael J. Cima is the David H. Koch Professor of Engineering and Professor of Materials Science and Engineering at MIT, serving as Faculty Director of the Lemelson-MIT Program since 2009. He joined MIT's faculty in 1986 after earning a BS in Chemistry and PhD in Chemical Engineering from UC Berkeley. His research focuses on materials and engineered systems for improving human health, particularly in cancer treatment, metabolic disorders, and implantable medical devices. Key innovations include MIT's three-dimensional printing process, chemically derived epitaxial oxide films for superconductors, and implantable MEMS devices for drug delivery and diagnostics. Cima holds over 300 peer-reviewed publications and 90 patents. His research interests span medical device development, biomaterials, and translational technologies like non-invasive diagnostic tools for liver disease and bladder cancer therapies. Awards include membership in the National Academy of Engineering (2011) and National Academy of Inventors (2016), as well as the W. David Kingery Award (2019). The Cima Lab, under his leadership, pioneers advanced materials and medical technologies.

Kirill VeselkovView profile

Associate Professor

• Artificial Intelligence
• Cancer Informatics
• Metabolomics
• +4 more

Dr. Kirill Veselkov is an Associate Professor in Cancer Informatics at Imperial College London's Department of Surgery & Cancer. He leads the DReaMLAB, developing AI-driven frameworks to integrate omics data into clinical decision-making and population health management. His work focuses on computational methods for precision medicine, drug repositioning, and digital pathology. Research Interests: Veselkov's expertise spans machine learning, metabolomics, and imaging informatics. He pioneers projects like DreamLab-DRUGS and CORONA-AI, leveraging citizen science and smartphone computing to discover disease-beating molecules in foods and drugs. Key areas include Hyperfoods for disease mitigation, AI-driven diagnostics (e.g., breath tests for colorectal cancer), and network-based approaches for cancer metabolism analysis. Awards: Recipient of the World Economic Forum Young Scientist Award, featured in BBC Click and Sky Swipe. His platforms like MSHub and ChemDistiller revolutionize mass spectrometry data processing. Collaborations with Vodafone Foundation highlight his translational impact. Labs/Teams: Directs the DReaMLAB, collaborating across Imperial's AI Network and Computational Medicine divisions. Active in the Microbiome Network and Pharmacology initiatives.

• Biosensing and Diagnostics
• Materials Science
• Volatile Analysis
• +8 more

Dr. Ben de Lacy Costello is an Associate Professor in Biosensing and Diagnostics at the University of the West of England (UWE), based in the Faculty of Health and Applied Sciences (HAS - Applied Sciences). His research focuses on gas sensor development, volatile analysis for disease detection, and unconventional computing using chemical systems such as liquid marbles and slime moulds. He collaborates with institutions like the University of Liverpool, Samsung, and the University of Freiburg. Education: PhD in Gas Sensor Fabrication for Food Spoilage Detection BSc in Materials Science Research Interests: Development of sensor arrays for disease biomarker detection (e.g., inflammatory bowel disease, bladder cancer) Chemical computing and pattern formation in excitable systems (e.g., Belousov-Zhabotinsky reactions) Memristor networks and bio-inspired electronic devices Application of volatile organic compound (VOC) analysis in clinical diagnostics His publications emphasize hyphenated techniques like GC-MS for VOC profiling and explore interdisciplinary approaches merging materials science with computational biology. His work on slime mould (Physarum polycephalum) has pioneered bio-hybrid computing systems. Collaborative projects include antibiotic susceptibility testing via VOCs and environmental sensor innovation with industrial partners like Samsung. Grants & Teams: Unconventional Computing Group at UWE Key contributor to interdisciplinary health tech projects Labs/Teams: Leading the Bio-inspired Sensors Lab at UWE Collaboration with the Bristol Urological Institute for urinary biomarker research

Rumana OmarView profile

Professor

• Biostatistics
• Medical Statistics
• Risk Prediction Models
• +7 more

Rumana Omar is a Professor of Medical Statistics at University College London's Department of Statistical Science, leading the Biostatistics Group at the NIHR UCLH/UCL Biomedical Research Centre. She provides statistical leadership for the UCL PRIMENT Clinical Trials Unit and has held prior appointments at Imperial College, London School of Hygiene & Tropical Medicine, and Queen Mary University of London. She holds a PhD in Statistics from the University of Reading (1991). Her research focuses on risk prediction models, missing data methodologies, cluster data analysis, and trials methodology, with applications in cardiology, oncology, dementia, and public health interventions. Her work spans methodological advancements in clinical trial design, cost-effectiveness analyses, and translational research. Notable contributions include developing risk prediction tools for sudden cardiac death in hypertrophic cardiomyopathy patients and evaluating interventions for hearing loss in dementia prevention. Leadership roles: NIHR Rapid Review Sub-Panel (2020), NIHR HTA General Board (2016–2020), MRC Fellowship Panel (2014–2018) Editorial roles: BMC Research Methodology (2016–2019) Awards and honors include elected membership in the International Society for Clinical Biostatistics (2004–2008) and committee roles in the Royal Statistical Society's Medical Section (2014–2019). Her grants and projects include the VALID trial assessing community occupational therapy for dementia carers, the CADMUS imaging trial for prostate cancer, and the LOGIC study on gender identity development in children. Collaborations emphasize interdisciplinary teams across biostatistics, clinical medicine, and public health.

Gregory A SmithView profile

Professor

• Virology
• Neuroscience
• Microbiology
• +5 more

Gregory A. Smith, PhD, is a Professor in the Department of Microbiology-Immunology at the Northwestern University Feinberg School of Medicine. His laboratory focuses on understanding neuroinvasive herpesviruses, particularly their molecular mechanisms of propagation and nervous system dissemination. Research combines live-cell microscopy, molecular genetics, and neuronal cell biology to study viral particle dynamics and axon transport. Key goals include identifying antiviral targets and engineering viral vectors for gene delivery. Smith holds a BA from UC Santa Barbara (1991), a PhD from the University of Pennsylvania (1996), and postdoctoral training at Princeton University (2001). Education: BA: University of California, Santa Barbara (1991) PhD: University of Pennsylvania (1996) Postdoctoral Fellow: Princeton University, Virology (2001) Research Interests: Neuroinvasion mechanisms, herpesvirus pathogenesis, axon transport dynamics, viral capsid assembly, molecular interactions in neuronal infection, and antiviral strategies. Awards: Fellow, Henry Kunkel Society (2019) Cold Sore Research Foundation Fellowship (2008) Burroughs Wellcome Fund Investigators Award (2005) Schweppe Foundation Career Development Award (2003) Professional Roles: Editor for mSphere and Journal of Virology ; Scientific Advisor for the International Herpesvirus Workshop; Founding member of the Chicago Area Virology Association. Affiliations: Northwestern University Institute of Neuroscience, Robert H. Lurie Comprehensive Cancer Center. Advising: Mentors students including Osefame Ewaleifoh (PhD/MPH), investigating HSV-1 encephalitis susceptibility and viral transport energetics. Labs/Teams: Directs a lab studying herpesvirus-cell interactions, with collaborations in gene therapy and vaccine development.

Steven ConollyView profile

Professor

• Medical Imaging
• Biosystems & Computational Biology
• Magnetic Particle Imaging (MPI)
• +4 more

Steven Conolly is a Full Professor of Bioengineering and Electrical Engineering and Computer Sciences at UC Berkeley, holding the Montford G. Cook Endowed Chair. He currently serves as Vice Chair of Instruction in BioE and previously chaired the UC Berkeley-UCSF Joint Graduate Group in Bioengineering (2006-2009). His research focuses on medical imaging hardware and biosensing, particularly Magnetic Particle Imaging (MPI), for applications like stem cell tracking, cancer imaging, and gastrointestinal health assessment. He has pioneered MPI scanner development in the USA and holds 30 patents, with over half licensed commercially. His work has been supported by CIRM, NIH, the Siebel Foundation, and others. Education: PhD in Electrical Engineering (Stanford University, 1989), M.S. and B.S. in Electrical Engineering (Stanford and Boston University). Research Interests: MPI technology advancement, nanoparticle design for imaging, and translational applications in diagnostics and therapy. His lab develops novel tracers and systems for imaging vascular structures, immune responses, and tumor biology using non-radioactive methods. Awards & Honors: Bakar Prize (2022), AIMBE Fellow (2015), NAE Gilbreth Lectureship (2006), and Stanford's Outstanding Inventor Award (2004). Grants & Patents: Secured major funding for MPI research and holds patents in imaging hardware and nanoparticle formulations. His innovations bridge fundamental physics with clinical applications. Lab & Collaborations: Leads a multidisciplinary team advancing MPI as a next-generation imaging modality. Collaborates with institutions on theranostic platforms combining imaging and therapy delivery.

Steve ConollyView profile

Professor

• Bioinstrumentation
• Biomaterials & Nanotechnology
• Magnetic Particle Imaging (MPI)
• +3 more

Steve Conolly is the Montford G. Cook Professor of Bioengineering and Professor of Electrical Engineering & Computer Sciences at the University of California, Berkeley. He leads the Conolly Lab, renowned for pioneering advancements in Magnetic Particle Imaging (MPI), including the world’s highest spatial resolution MPI scanner, projection MPI technology, and 3D Projection-Reconstruction MPI systems. His research focuses on developing novel biomedical imaging modalities, particularly leveraging magnetic nanoparticles for applications in cell tracking, vascular imaging, and cancer diagnostics. His lab’s innovations span hardware design, nanoparticle optimization, and clinical translation of MPI for non-invasive diagnostics. Key research areas include superparamagnetic and superferromagnetic nanoparticle characterization, MPI system optimization, and theranostic platforms combining imaging with therapies like magnetic hyperthermia. Publications highlight breakthroughs in MPI resolution, nanoparticle behavior under thermal and magnetic fields, and clinical applications such as gastrointestinal health monitoring, CAR-T cell tracking, and stroke imaging. Conolly’s work bridges electrical engineering, bioengineering, and clinical medicine, advancing MPI toward widespread medical adoption.

• Neuroblastoma
• Rhabdomyosarcoma
• Tumor Heterogeneity
• +7 more

Kasper Karlsson is a Senior Research Specialist at the Department of Oncology-Pathology, Karolinska Institutet, leading a research group focused on overcoming tumor heterogeneity in childhood cancers like neuroblastoma and rhabdomyosarcoma. He previously served as an Assistant Professor at the same department from 2021 to 2025. Employment: Senior Research Specialist (2025–present), Assistant Professor (2021–2025) Education: Medicine Doctoral degree in Medical Biochemistry and Biophysics, Karolinska Institutet (2016) His research employs cutting-edge approaches such as organoid modeling , expressed cell barcoding , single-cell sequencing , and high-throughput drug screening to develop precision strategies like Precision Lethality for targeting resistant tumor clones. Current projects include molecular radiotherapy and CRISPR/Cas9-based tumor modeling. In the last decade, Karlsson has published in top-tier journals (e.g., Nature , Cell ), focusing on cancer biology, stem cell research, and genomic analysis. His work bridges translational oncology with medical biotechnology , emphasizing tumor evolution and therapeutic resistance. Scientific Awards European Research Council Starting Grant (2023) Research Grants Swedish Research Council (2024–2027) Swedish Cancer Society (2024) Childhood Cancer Foundation (2024) European Research Council (2024–2028) As a mentor, he supervises doctoral students including Myra Almen and Cheng-De Liu. His lab collaborates with institutions like SciLifeLab and Radiumhemmet, contributing to precision medicine and cancer survival improvements.

• Exercise Physiology
• Health-Enhancing Physical Activity
• Exercise and Ageing
• +5 more

Professor Stephen Bird is a Professor of Exercise and Sport Science at the School of Health Sciences, Swinburne University . With over 35 years of academic and industry experience in exercise physiology, he has contributed to research in chronic disease prevention, telehealth delivery, and athlete development.

Kimmie NgView profile

Associate Professor

• Colorectal Cancer
• Gastrointestinal Oncology
• Medical Oncology
• +5 more

Kimmie Ng is an Associate Professor of Medicine at Harvard Medical School and Associate Chief of the Division of Gastrointestinal Oncology at Dana-Farber Cancer Institute in Boston, MA. She directs the Young-Onset Colorectal Cancer Center and co-directs the Colon and Rectal Cancer Center, pioneering multidisciplinary approaches to colorectal cancer. Yale University (BS) University of Pennsylvania Perelman School of Medicine (MD) Harvard T.H. Chan School of Public Health (MPH) Her research integrates molecular epidemiology , nutritional oncology , and microbiome studies to identify predictors of cancer survival. Recent work explores HER2-targeted therapies , vitamin D pathways , and metabolic biomarkers in gastrointestinal cancers. Recent publications highlight her expertise in liquid biopsy epigenomics , immune checkpoint inhibitors , and diet-cancer interactions . She has secured multiple grants including NIH K07 , R01 , and P50 SPORE awards . Dr. Ng chairs ASCO’s Scientific Program Committee and serves on its Nominating Committee. She is also an Associate Editor at JAMA and frequently appears in media outlets like NYTimes and CNN to raise awareness about young-onset colorectal cancer.

• Prostate Cancer
• Bladder Cancer
• Cancer Stem Cells
• +5 more

Professor Rakesh Heer is affiliated with Newcastle University and actively contributes to prostate and bladder cancer research. His work focuses on molecular mechanisms, stem cell dynamics, and translational approaches. Academic Rank: Professor Research Themes: Prostate Cancer, Bladder Cancer, Cancer Stem Cells, Induced Pluripotent Stem Cells (iPSCs), Androgen Receptor Signaling, Glycosylation Pathways Recent publications highlight his exploration of glycobiology in prostate cancer immunity (e.g., ST3Gal1 and ST6GAL1 roles) and AI applications in bladder cancer recurrence prediction. He also investigates OXPHOS defects , prostate organoids , and clinical trial methodologies for castration-resistant prostate cancer. Professor Heer collaborates extensively on iPSC-based cancer models and urological surgical techniques , including photodynamic diagnosis and focal therapy. His work bridges fundamental molecular biology, translational research, and clinical practice.

• Urology
• Urological Oncology
• Prostate Cancer
• +7 more

Dr. Trevor Dorkin is a researcher at Newcastle University, affiliated with the Faculty of Medical Sciences and the Institute of Cellular Medicine. He has made sustained contributions to urology, particularly in clinical urology, urological oncology, and surgical outcomes. His work spans from molecular pathology to health services research and clinical guidelines. Research Interests: His primary fields include Urology , Prostate Cancer , Urethral Stricture , Testicular Torsion , Laparoscopic Surgery , and Molecular Pathology . His research integrates clinical practice with molecular analysis, aiming to improve diagnostic accuracy and treatment outcomes. The recent publications, including the 2022 BURST-BAUS consensus document and the 2021 OPEN trial cost-effectiveness analysis, reflect a strong trend toward evidence-based practice, guideline development, and health economic evaluation in urological care. Earlier works focus on molecular mechanisms in prostate cancer, showing a long-standing interest in oncological pathways and biomarkers. Dr. Dorkin has collaborated extensively with leading urological researchers such as Professor Christopher Harding, Rob Pickard, and Professor David Neal. While no formal awards are listed, his involvement in high-impact clinical trials and systematic reviews underscores his role in advancing urological science. Advising and Grants: There is no explicit mention of students or grant funding in the provided text. However, his repeated involvement in multi-center studies suggests participation in collaborative research networks and likely access to external funding. Labs and Teams: Dr. Dorkin appears to be part of a broader urological research group at Newcastle University, contributing to both clinical and molecular research streams. His work with the BURST-BAUS group indicates active participation in national consensus-building initiatives in urology.

Tan Phat HuynhView profile

Associate Professor

• Materials Science
• Nanotechnology
• Biocompatibility
• +7 more

Tan Phat Huynh is an Associate Professor (tenure track, level 2) at Åbo Akademi University’s Faculty of Science and Engineering, Department of Chemistry and Chemical Engineering. His research focuses on materials science, metabolomics, and sustainable sensor technology. Education: Doctorate in Physical Chemistry, Polish Academy of Sciences Research Interests: Development of biocompatible nanocomposites and hydrogels Non-invasive cancer diagnosis via NMR metabolomics Machine learning for medical diagnostics Green technology and sustainable materials Wearable and plant-inspired sensors Publication Trends: Recent work emphasizes prostate cancer biomarker detection through metabolomics, sustainable hemicellulose-based sensors, and advanced algorithms like Protomix for NMR data analysis. Collaborative projects span molecularly imprinted polymers, self-healing materials, and international education initiatives. Grants and Collaborations: He leads projects funded by the Academy of Finland and Finnish Education and Culture Ministry, including a double-degree program with IIT Mandi. Collaborations involve Finnish-Indian research networks and Ukraine education rebuilding efforts. Lab and Team: His work integrates molecular engineering with clinical applications, supported by Åbo Akademi’s Printed Intelligence Infrastructure project and international academic visitors hosted in 2024.

Alessandro MarconView profile

Researcher

• Health information dissemination
• Media representation of health policy
• Genetics
• +7 more

Alessandro Marcon is a Senior Researcher at the Health Law Institute, University of Alberta, focusing on health information dissemination through media channels. His research explores how platforms like Google, Twitter, and Reddit shape public understanding of genetics, vaccination, and alternative therapies. He holds a 2015 MA in Applied Linguistics and Discourse Studies with a Digital Humanities specialization from Carleton University. His work analyzes the ethical implications of digital marketing in healthcare, particularly in contexts like Google ads for alternative cancer clinics and social media discussions around prenatal testing. Research Trends His recent articles examine how online advertising (e.g., Google ad spaces used by alternative cancer clinics) and social media discourse (e.g., Reddit's subjective interpretations of NIPT risk ratios) influence health decision-making and public policy. Scientific Awards Research funded by CIHR (Canadian Institutes of Health Research) Collaborative projects supported by Genome Canada and Genome Alberta Advising & Grants Collaborates with interdisciplinary teams on health law and policy research. No formal student advising roles are mentioned, but contributes to public discourse through media outreach and community engagement. Labs & Teams Works at the Health Law Institute, University of Alberta, engaging with global health policy experts and digital ethics researchers.

• Precision Medicine
• Medical Oncology
• Cancer Research
• +4 more

Giuseppe Badalamenti is an Associate Professor at the University of Palermo's School of Medicine and Surgery, specializing in Precision Medicine within Medical, Surgical and Critical Care Areas. His research focuses on advanced cancer therapies, particularly gastrointestinal stromal tumors (GIST), sarcomas, neuroendocrine tumors, and melanoma. EURACAN European Reference Center in Palermo Medical Oncology Unit affiliation Research Interests: He investigates molecular classification systems, tyrosine kinase inhibitor response/resistance mechanisms, liquid biopsy applications, and multidisciplinary approaches to rare cancers. Publications: Recent work includes studies on Desmoid Fibromatosis (2024), GIST molecular subtyping (2023), liposarcoma therapies (2022), and pancreatic neuroendocrine tumors (2019). Collaborations: Active in the EURACAN network for rare cancer research, with clinical focus on: Sarcoma treatment Liquid biopsy monitoring Immunotherapy toxicity management Neuroendocrine tumor therapies